What does a reportable test actually cost you?
Ask most laboratories what a test costs and they will quote the reagent price. But a released result is the sum of many things, and the parts nobody counts are usually the ones eating the margin.
A lab that wants to be profitable needs to know what each test costs, where the money leaks, and what price holds the margin. Here is how to judge the tooling that promises it.
A laboratory that wants to be profitable cannot get there on instinct. Profit is the gap between what a test costs and what it earns, and a lab that does not know the first half of that equation is managing the second half blind. Cost intelligence, by which we mean knowing the true cost of each test, where the money leaks, and what price holds the margin, is not a luxury for the well-resourced lab. It is the foundation a profitable lab stands on. The question for a buyer is not whether to invest in cost intelligence, but how to tell genuine cost intelligence from a tool that produces tidy numbers nobody can defend.
This is a buyer’s guide to that judgement: what real cost intelligence has to do, and the tests that separate it from a spreadsheet with a nicer interface.
Three things. First, it must build a true cost per test from every component, not just the reagent: the consumables a run draws, the quality control it shares, the wastage it carries, and a fair share of overhead. A cost that omits the hard-to-count ingredients is not a true cost, and a tool that only consolidates the easy ones is not doing the job.
Second, it must compare what a test should cost against what it actually consumed, and name the driver of any gap. A figure with no expected-versus-actual comparison cannot find a leak. A variance with no driver attached cannot tell you what to do about it. Real cost intelligence does both, so the lab fixes the few tests moving the number instead of trimming everywhere.
Third, it must let the lab price with confidence, by test, by instrument, and over time, so prices sit a deliberate distance above real cost and can be defended in a tender or a payer negotiation. Costing that cannot inform a price is an accounting curiosity, not a business tool.
The single most important question to ask of any cost-intelligence tool is where its numbers come from. A tool that asks you to enter reagent prices, consumption rates and overheads into its own database is a spreadsheet in disguise. Its numbers are accurate the day you enter them and wrong every day after, because the lab’s reality, reagent prices, stock issues, wastage, moves constantly and the tool does not move with it. Keeping it current is a job nobody sustains, so the costing drifts and the lab quietly goes back to guessing.
Real cost intelligence reads the books the lab already runs. The component costs come from the same stock valuation the rest of the operation posts. The overheads come from the same general ledger that runs the finance. When a reagent price changes or stock is issued, the cost moves on its own, with no spreadsheet to maintain and no reconciliation to perform. Native costing stays true because it is not a copy of the truth, it is the truth, read directly.
The fastest way to judge a cost-intelligence tool is to ask where the numbers live. If they live in the tool’s own spreadsheet, they will be wrong by next month. If they live in the books the lab already runs, they stay true on their own.
Veona Cost Per Reportable Test is built natively on the lab’s own stock and ledger. Component costs are drawn from stock at weighted-average cost, overheads from the general ledger, so the cost per reportable test consolidates reagents, controls, wastage and overhead from the real books and moves the moment a price or an issue does. It compares expected against actual, flags the variance and names the driver, and lets the lab slice cost by instrument and over time, so prices can be set and defended on real margin. There is no parallel spreadsheet, because there is nothing to copy: it reads the operation the lab is already running.
If you are weighing this, the earlier pieces in this series show the parts in detail, from what a reportable test actually costs to pricing a menu on the real number.
For a laboratory in Nigeria or across the region, cost intelligence is not a refinement on a comfortable margin, it is survival on a thin one. Reagents are imported and dollar-priced, so cost rises with every move in the exchange rate, often faster than a lab can react. Margins leave no room to carry loss-making tests on instinct. And competition on price is real, so the lab that knows its true cost can price to win work while still protecting its margin, where a rival guessing at cost either prices itself out or sells at a loss.
A lab that wants to be profitable in this market needs costing it can trust, kept current without manual effort, defensible in a negotiation. That is the bar, and it is the bar a native tool clears and a spreadsheet cannot.
See cost intelligence built natively on your own books, true today and true next month. Book a demo and we will walk it through on your numbers.
Ask most laboratories what a test costs and they will quote the reagent price. But a released result is the sum of many things, and the parts nobody counts are usually the ones eating the margin.
A planned cost tells you what a test should consume. The real stock draws tell you what it did. The gap between them is where a lab finds the money it has been losing without knowing.
Margin rarely leaks evenly. A handful of tests, running far over what they should cost, usually drains more than the rest combined. The trick is finding them before they find your bottom line.
We will tailor a demo to how your hospital, clinic, or lab actually runs, offline behaviour, payments, reporting, and all.